Announced at the May 2008 American Society for Aesthetic Plastic Surgery, an upcoming Lipodissolve clinical trial will begin through The Aesthetic Surgery Research Foundation to study more about the methodology behind lipodissolve.
Lipodissolve is performed through an injection of medications that dissolve localized areas of fat, offering a less invasive approach to liposuction. In fact, lipodissolve can treat areas that traditional liposuction may not. Areas of the face, neck and other small localized areas may be treated with lipodissolve. In addition, lipodissolve can treat cellulite. This can be extremely advantageous as no other recognized treatment for cellulite compares to the results that can be accomplished through lipodissolve.
Revisiting Through Clinical Trial
The focus of the clinical trial for lipodissolve is to clarify the effect that the medications might have on the cells and tissues in the body. Currently, liposuction is the only FDA approved method for the safe, effective and permanent removal of fat cells.
During the clinical trial, twenty patients will receive lipodissolve in the lower abdomen in several sessions that will occur eight weeks apart. Each participant will undergo blood tests, biopsy, MRI and DEXA body fat testing to help determine the safety and effectiveness of lipodissolve treatment.
It is important to note that the combination of medications used in lipodissolve varies among physicians. The ASERF will be using one combination of medications in the clinical trial.
Identifiable Outcome Markers
In the end, the results of the study should provide information regarding the possible risks that may be associated with lipodissolve, including: implication for tissue necrosis (death), tissue repair ability, immunity complications, scarring or granuloma formation. Though, lipodissolve currently holds promise among many plastic surgeons as a viable alternative to liposuction.
Back to List of Articles